Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists
Lenalidomide (L) is approved for treating multiple myeloma (MM), being preferred to its parent drug, thalidomide, for its superior safety. We report the case of a patient developing more than 10 basal cell carcinomas (BCCs) within 1 month of starting L. Notably, his treating hematologist neither rec...
Bewaard in:
| Hoofdauteurs: | , , |
|---|---|
| Formaat: | Boek |
| Gepubliceerd in: |
PAGEPress Publications,
2022-07-01T00:00:00Z.
|
| Onderwerpen: | |
| Online toegang: | Connect to this object online. |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Internet
Connect to this object online.3rd Floor Main Library
| Plaatsingsnummer: |
A1234.567 |
|---|---|
| Kopie 1 | Beschikbaar |